Already have an ACS ID?
Renew your membership, and continue to enjoy these benefits.
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Already have an ACS ID? Log in here
Already an ACS Member?
Log in here
Choose the membership that is right for you. Discounts will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Your account has been created successfully, and a confirmation email is on the way.
Your username is now your ACS ID.
Most Popular in Pharmaceuticals
To download a pdf of this article, visit http://cenm.ag/platinumdrugs.
References used to create this graphic:
The resurgence of platinum-based cancer chemotherapy
Cisplatin celebration and cancer research symposium
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
Mechanisms of platinum drug resistance
The status of platinum anticancer drugs in the clinic and in clinical trials
Pt-based drugs: the spotlight will be on proteins.
A Drug of Such Damned Nature.1 Challenges and Opportunities in Translational Platinum Drug Research.
A collaboration between C&EN and Andy Brunning, author of the popular graphics blog Compound Interest
To see more of Brunning’s work, go to compoundchem.com. To see all of C&EN’s Periodic Graphics, visit cenm.ag/periodicgraphics.
This article has been sent to the following recipient: